The UAE’s Clinical Trials Moment: How New Federal Laws and Tax Credits are Re‑shaping Research

9 min 42 sec February 6, 2026 (Edited)

Written by

Andrea Tithecott

Partner

a.tithecott@tamimi.com View LinkedIn Profile

The United Arab Emirates has overhauled the rules of the game for clinical trials. The legal framework is now more innovation friendly than at any point in the country’s history, and a new research and development tax credit, effective 1 January 2026, is poised to amplify momentum.

This article explains what these laws do, why they matter for sponsors and investigators, and how the forthcoming R&D tax credit could tilt business cases in favour of running trials in the UAE. It reflects the law and available guidance as of early January 2026, noting that several executive regulations and tax rules are still to come.

The federal framework

Federal Decree‑Law No. 28 of 2023 created the Emirates Drug Establishment (EDE), the federal medicines authority that is the single point of contact for medical products and research oversight. The creation of the EDE has reshaped federal oversight by placing the full lifecycle of medical products — testing, licensing, import/export, market approval, pricing, pharmacovigilance — under a single authority.

For clinical trials, that institutional clarity matters. The EDE is charged with preparing the national framework for pharmacological research and clinical and non‑clinical trials, authorising entities that conduct them, and supervising compliance. The EDE presents a single, accountable federal counterpart that can coordinate with emirate‑level health authorities and drive policy through executive regulations and guidance, supported by local emirate regulations, research standards, and licensure.

Pharmacy Law 38, which entered into force on 2 January 2025, supplies the substantive rules on the regulation of medical products. Often called the Pharmacy Law, it consolidates clinical research controls, licensing, and approvals into a coherent national system. It defines clinical research and clinical trials, sets a baseline that trials cannot begin until adequate non‑clinical studies show an initial safety profile, and requires that research entities be licensed and obtain all necessary approvals before commencing.

The law contemplates a Cabinet‑issued framework of terms and controls for clinical research, signalling that more detailed procedures — authorisation flows, documentation requirements, and supervisory mechanisms — will be codified at federal level. In the interim, sponsors rely on Good Clinical Practice guidance already in force and on emirate‑level procedures that operationalise those standards.

Pharmacy Law 38 establishes a modern toolkit for product authorisation that interacts with research. Conditional marketing approvals allow time‑limited access in specific circumstances. Emergency use authorisations can be issued during declared health emergencies. A fast‑track route for innovative therapies with therapeutic importance is mandated.

These measures do not short circuit the conventional separation between investigational use and commercial marketing, but they do create pragmatic regulatory levers that can support development programmes and provide pathways to rapid access once the evidence supports it.

The law further enables the licensing of contractual companies for research and development — capturing contract research organisations (  and site management organisations — thereby normalising the outsourced trial operations model that global sponsors use.

The law also creates a licensing regime for biobanks with quality systems, sample tracking, adverse event reporting, and transfer controls. That matters in practice because many modern trials depend on biological sampling and storage at scale, from routine pharmacokinetics to cell and gene therapy programmes. With biobanks now explicitly regulated, sponsors and academic partners have a clear route to establish repositories and to import or export samples under EDE permits that are aligned with health sector data and genomic rules.

Emirate‑level execution: Dubai and Abu Dhabi pathways

While the EDE is the federal anchor, clinical research is practiced in the emirates, and Dubai and Abu Dhabi have built mature processes that dovetail with federal law.

Abu Dhabi’s Department of Health layers robust governance on top of the federal baseline through a human subject research standard and specific clinical trial guidelines for investigational products and devices. These instruments define ethics committee procedures, mandate good clinical practice, and create departmental review and appeal mechanisms. Abu Dhabi stands out for its genomic data requirements: raw genomic data must be archived within the emirate, cloud use is restricted, and outsourcing outside the UAE is barred without regulatory approval.

Data‑rich or genomics‑heavy trials necessitate local bioinformatics infrastructure and carefully controlled access models. Combined with investment hubs like Hub71 in the Abu Dhabi Global Market, Lifesciences ecosystems such as the Masdar City free zone biotech cluster, and M42 group clinical trials programmes led through the Emirati Genome Program and Cleveland Clinic Abu Dhabi, Abu Dhabi is at the forefront of clinical trials investment in the UAE.

In Dubai, the Dubai Health Authority (DHA) requires approval from the Dubai Scientific Research Ethics Committee, insists on Good Clinical Practice‑certified investigators, and enforces rigorous informed consent, safety reporting, and data‑privacy controls. Dubai’s public health framework extends across the emirate, including free zones, integrating permits, inspection, and penalties in a consistent way. That unity simplifies multi‑site studies that might span both onshore and free-zone healthcare providers. The growth of the sector in Dubai is spearheaded though Dubai Health’s Mohammed Bin Rashid University of Health Sciences and its recently created Genomic Medicine Center, together with the Dubai Science Park leading a biotech cluster.

Dubai Healthcare City, the free zone that hosts an extensive clinical ecosystem, runs a research oversight regime aligned with federal and emirate law. It permits genetic research under ethics committee supervision, prefers UAE‑based analysis, allows sample export with safeguards, and restricts secondary use of samples without fresh approvals. The result is a three‑layered but coherent system: federal rules and approvals sit atop emirate ethics review and operational oversight, with free zone specificity where appropriate.

Guardrails: Data, genomics, and biobanks

The UAE’s personal data protection law classifies health and genetic data as sensitive and requires explicit consent, purpose limitation, security controls, and careful cross‑border transfer mechanisms. Sectoral health data rules generally prohibit storing or transferring health data related to services provided in the UAE outside the country, subject to defined exceptions, including scientific research approved by the relevant health authority and pharmacovigilance.

In practical terms, sponsors can move data when an approved research programme requires it, but they must design consent forms, governance, and security to meet both general data protection and health sector requirements.

The Human Genome Law is decisive for gene therapy and genetic research. It permits gene therapy under strict clinical controls, mandates informed consent for genetic and genomic screening, and regulates the taking, analysis, use, preservation, and transfer of biological samples, with restrictions on storage and transfer outside the UAE unless approvals are granted. Abu Dhabi’s stricter genomic data localisation sits on top of that federal baseline. Together, these rules do not foreclose genomics research, but they do force localisation (except where cross-border collaborations are beneficial and with regulatory approval), segregation from unrelated databases, explicit consent and counselling pathways, and traceable sample logistics.

Against this backdrop, Pharmacy Law 38’s biobank licensing regime is an enabler. It brings sample collection, preservation, import/export, and safety reporting into an auditable system that can interoperate with clinical sites and laboratories. For cell and gene therapy, cord blood and stem cell rules provide a complementary operational framework for licensed storage centres, including required donor testing and end‑to‑end controls. The message for sponsors is that the UAE welcomes advanced modalities, provided projects are engineered to respect the data and sample localisation perimeter.

Why the UAE is now more trial friendly than ever before

The UAE’s clinical trials environment is maturing in ways that reduce friction and reward innovation. Good Clinical Practice standards are baked into federal guidance and emirate procedures, so global sponsors can lift and shift familiar quality systems. The EDE’s single‑window oversight simplifies import permits for investigational products, pharmacovigilance reporting, and the interface between ethics and regulatory approvals. Conditional, emergency, and fast‑track pathways align the development cycle with accelerated access options once the science justifies them. And for originators, an eight‑year data exclusivity period for innovative pharmaceuticals strengthens expectations around eventual market entry and shapes investment models.

There is also a policy signal worth noting. The EDE has aligned formulary governance with a National Essential Medicines List, indicating that market access will increasingly track national policy instruments. That alignment suggests sponsors should plan early for post‑trial access discussions, cost effectiveness narratives, and pharmacovigilance commitments that can bridge the gap from clinical use to broader reimbursement decisions.

The tax catalyst from 1 January 2026

Effective 1 January 2026, the UAE has introduced an R&D tax incentive that can materially change the economics of running trials locally. The incentive is a refundable tax credit in the range of 30 to 50 percent of eligible R&D expenditure, grounded in OECD Frascati definitions of research and experimental development. The refundable nature means that even loss‑making or early‑stage entities can receive a cash refund where the credit exceeds corporate tax liability, a feature that resonates with biotech and med‑tech companies in extended development phases.

Eligible cost categories are expected to include R&D staff salaries, consumables, software, equipment depreciation, and payments to external research partners such as CROs and laboratories. The documentation bar will be high. Robust cost tracking, contemporaneous technical narratives demonstrating novelty and uncertainty, and clear segregation of qualifying work from routine testing will be needed for claims to withstand Federal Tax Authority (FTA) scrutiny.

The opportunity for clinical trial programmes is straightforward. Many trial activities — protocol design, biomarker method development, investigational product logistics and validation, and data analytics under uncertainty — map to qualifying R&D when appropriately documented. Development‑stage clinical studies linked to the creation or substantial improvement of medical products can align well.

Two caveats are essential. Executive regulations and detailed FTA guidance have not yet been issued, so definitions of eligible expenditure, documentation standards, and claim mechanics remain subject to change. There is also an interaction with free zone regimes and transfer pricing that needs careful design to ensure substance is where claimed and that related‑party charges reflect arm’s length principles.

In practice, sponsors and research institutions can mitigate uncertainty by establishing dedicated R&D entities and cost centres now, adopting global best‑practice project accounting, and drafting intra‑group agreements that align decision making, risk, and funding with the entities that will make the claim. Doing so from the start of 2026 ensures the full year’s eligible costs are captured once the regulations land.

Practical insights for sponsors, sites, and investors

The path to operational readiness is clearer than it may appear. Licensing is the foundation. Clinical and non‑clinical research entities must hold the appropriate licenses, and CROs and site management organisations are recognised under Pharmacy Law 38. Investigators should hold Good Clinical Practice certification, and laboratories need to meet accreditation standards within set timelines. Early engagement with ethics committees in Dubai or Abu Dhabi, paired with EDE dialogue on investigational product importation and sample handling, may compress review cycles and improve predictability.

Data and genomics deserve early attention. Sponsors should map data flows at project inception, distinguishing general health data — transferable abroad for approved research under strict conditions — from genomic data that may face stricter localisation, especially in Abu Dhabi. Consent language, data processing agreements, and cyber controls must be drafted to meet both the federal personal data regime and sectoral rules. Biobank partnerships should be formed with licensed repositories, and sample transfer plans should anticipate federal and emirate approval triggers for export or external analysis.

Finally, the R&D tax incentive uncertainty is not a reason to delay. With effective date certainty and refundable mechanics, the incentive rewards those who are ready sooner rather than later. If final guidance adjusts boundaries, a well‑documented programme can adapt without losing the core economic benefits.